By immunohistochemical staining of tissue microarray slides of NPC samples, we first found that an increased level of CXCR2 and CXCL8 predicts poor clinical outcomes which implies that CXCR2 is an attractive therapeutic target for NPC. The gene discussed is CXCR2; the disease is nasopharyngeal carcinoma.